The Japanese multinational pharma is pledging up to $580 million in a development and commercialization deal with AcuraStem for the latter’s PIKFYVE program for amyotrophic lateral sclerosis.
https://www.pharmalive.com/wp-content/uploads/2023/09/Takeda-Cambrige.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-09-26 08:44:332023-09-26 09:08:02Takeda puts nearly $600M on the line for AcuraStem’s ALS program
